Clinical Pharmacokinetics

, Volume 40, Issue 9, pp 661–684 | Cite as

The Nicotine Inhaler

Clinical Pharmacokinetics and Comparison with Other Nicotine Treatments
  • Nina G. Schneider
  • Richard E. Olmstead
  • Mikael A. Franzon
  • Erik Lunell
Review Articles Drug Disposition


Nicotine inhaled in smoke is the most rapid form of delivery of the drug. With smoking, arterial boli and high venous blood nicotine concentrations are produced within seconds and minutes, respectively. The potency of nicotine as the primary reinforcement in tobacco addiction is attributed to this rapid rate of delivery. By design, nicotine treatments reduce the rate and extent of drug delivery for weaning from nicotine during smoking cessation. Theoretically, they prevent relapse by reducing withdrawal and craving associated with the abrupt cessation of cigarettes.

The nicotine inhaler treats the complexity of smoking through weaning both from the drug and from the sensory/ritual components associated with smoking. The inhaler is ‘puffed’ but not lit and there is considerable ‘puffing’ required to achieve slower rising and lower nicotine concentrations. These factors allow it to be used as a nicotine reduction treatment.

One inhaler contains 10mg of nicotine (and 1mg of menthol) of which 4mg of nicotine can be extracted and 2mg are systemically available. Shallow or deep ‘puffing’ results in similar nicotine absorption. Nicotine is delivered mainly to the oral cavity, throat and upper respiratory tract with a minor fraction reaching the lungs. This was confirmed with positron emission tomography and by assessment of arterial concentrations. A single inhaler can be used for one 20-minute period of continuous puffing or periodic use of up to 400 puffs per inhaler.

With controlled puffing in laboratory testing, venous plasma nicotine concentrations from a single inhaler puffed 80 times over 20 minutes averaged 8.1 μg/L at 30 minutes. Lower concentrations of 6.4 to 6.9 μg/L have been reported for self-administration under clinical conditions. The time to peak plasma concentrations varies but is always significantly longer than with cigarette delivery. Estimates of nicotine intake from cotinine concentrations were higher than expected (60 to 70% of baseline smoking concentrations). This elevation may be due to the swallowing of nicotine and subsequent first-pass biotransformation to cotinine. In general, venous blood nicotine concentrations are considerably lower than with smoking and are within the range observed for other nicotine reduction therapies.

Efficacy trials show consistent superiority of the inhaler over placebo. Despite the ‘cigarette-like’ appearance of the inhaler and the associated sensory/ritual elements, little treatment dependence or abuse has been reported. This is attributed to the slow rise time and low nicotine blood concentrations. The inhaler is a valuable addition to treatment of tobacco dependence and can be used alone or with other treatments.


Nicotine Cotinine Harm Reduction Nicotine Patch Treatment Dependence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Drs Schneider and Olmstead were funded by the first author’s VA Merit Review and NIDA Grant #DA11398. Special thanks to Shilpan Patel M.A., and Regina Harris for help in preparing the manuscript.


  1. 1.
    U.S. Department of Health and Human Service. The health consequences of smoking: nicotine addiction. Washington, DC: Government Printing Office, 1988Google Scholar
  2. 2.
    Stolerman IP, Jarvis MJ. The scientific case that nicotine is addictive. Psychopharmacology 1995; 117: 2–10PubMedCrossRefGoogle Scholar
  3. 3.
    Russell MAH, Feyerabend C. Cigarette smoking: a dependence on high-nicotine boli. Drug Metab Rev 1978; 8(1): 29–57PubMedCrossRefGoogle Scholar
  4. 4.
    Gourlay SG, Benowitz NL. Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin Pharmacol Ther 1997; 62: 453–63PubMedCrossRefGoogle Scholar
  5. 5.
    Farre M, Cami J. Pharmacokinetic considerations in abuse liability evaluation. Br J Addict 1991; 86: 1601–6PubMedCrossRefGoogle Scholar
  6. 6.
    Henningfield JE, Keenan RM. Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 1993; 61(5): 743–50PubMedCrossRefGoogle Scholar
  7. 7.
    Ferno O, Lichtneckert SJA, Lundgren CEG. A substitute for tobacco smoking. Psychopharmacologia (Berl) 1973; 31: 201–4CrossRefGoogle Scholar
  8. 8.
    Schmitz JM, Schneider NG, Jarvik ME. Nicotine. In: Lowinson JH, Ruiz P, Millman RB, et al., editors. Substance abuse: a comprehensive textbook. 3rd ed. New York: Williams & Wilkins, 1997: 276–94Google Scholar
  9. 9.
    Okuyemi KS, Ahluwalia JS, Harris KJ. Pharmacotherapy of smoking cessation. Arch Fam Med 2000; 9(3): 270–81PubMedCrossRefGoogle Scholar
  10. 10.
    Wallstrom M, Nilsson F, Hirsch J-M. A randomised, doubleblind, placebo-controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation. Addiction 2000; 95(8): 1161–71PubMedGoogle Scholar
  11. 11.
    Glover ED, Glover PN, Franzon M, et al. A nicotine sublingual tablet for smoking cessation: 6-month data [abstract]. 10th World Conference on Tobacco or Health; 1997 Aug 24-28; Beijing. 138Google Scholar
  12. 12.
    Hajek P, West R, Foulds J, et al. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 1999; 159(17): 2033–8PubMedCrossRefGoogle Scholar
  13. 13.
    Schneider NG, Olmstead R, Nides MA, et al. Preference testing as a means of matching smokers to nicotine treatments [abstract]. Society for Research on Nicotine and Tobacco. Third Annual Scientific Conference; 1997 Jun 13–14; Nashville, TN. Addiction 1998; 93(6): 921Google Scholar
  14. 14.
    Schneider NG, Lunell E, Olmstead RE, et al. Clinical pharmacokinetics of nasal nicotine delivery. Clin Pharmacokinet 1996; 31(1): 65–80PubMedCrossRefGoogle Scholar
  15. 15.
    Hardman JGG, Gilman AG, Limbird LL, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1995Google Scholar
  16. 16.
    Benowitz NL. Summary: risks and benefits of nicotine. In: Benowitz NL, editor. Nicotine safety and toxicity. New York: Oxford University Press, 1998: 185–94Google Scholar
  17. 17.
    Jarvik ME, Schneider NG. Nicotine. In: Lowinson JH, Ruiz P, Millman RB, et al., editors. Substance abuse: a comprehensive textbook. 2nd ed. New York: Williams & Wilkins, 1992: 334–56Google Scholar
  18. 18.
    Benowitz NL. Nicotine replacement therapy: what has been accomplished—can we do better? Drugs 1993; 45: 157–70PubMedCrossRefGoogle Scholar
  19. 19.
    Henningfield JE, Heischman SJ. Behavioral toxicology of nicotine. In: Benowitz NL, editor. Nicotine safety and toxicity. New York: Oxford University Press, 1998: 133–46Google Scholar
  20. 20.
    Rose JE, Behm FM, Westman EC, et al. Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: implications for addiction. Drug Alcohol Depend 1999; 56(2): 99–107PubMedCrossRefGoogle Scholar
  21. 21.
    Benowitz NL, Jacob III P, Savanapridi C. Determinants of nicotine intake while chewing nicotine polacrilex gum. Clin Pharmacol Ther 1987; 41: 467–73PubMedCrossRefGoogle Scholar
  22. 22.
    Lunell E, Molander L, Leischow SJ, et al. The effect of nicotine vapour inhalation on the relief of tobacco withdrawal symptoms. Eur J Clin Pharmacol 1995; 48(3-4): 235–40PubMedCrossRefGoogle Scholar
  23. 23.
    Russell MAH, Sutton SR, Feyerabend C, et al. Nicotine chewing gum as a substitute for smoking. BMJ 1977; 1(6068): 1060–3PubMedCrossRefGoogle Scholar
  24. 24.
    Russell MAH, Jarvis MJ. Theoretical background and clinical use of nicotine chewing gum. NIDA Research Monogr 1985; 53: 110–30Google Scholar
  25. 25.
    Russell MAH, Raw M, Jarvis MJ. Clinicaluse ofnicotine chewing-gum. BMJ 1980; 280: 1599–602PubMedCrossRefGoogle Scholar
  26. 26.
    Benowitz NL, Jacob P, Jones RT, et al. Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther 1982; 221: 368–72PubMedGoogle Scholar
  27. 27.
    Benowitz NL, Zevin S, Jacob III P. Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking. Br J Clin Pharmacol 1997; 43(3): 259–67PubMedCrossRefGoogle Scholar
  28. 28.
    Henningfield JE, London ED, Benowitz NL. Arterial-venous differences in plasma concentrations of nicotine after cigarette smoking. JAMA 1990; 263(15): 2049–50PubMedCrossRefGoogle Scholar
  29. 29.
    Rand MJ. Neuropharmacological effect of nicotine in relation to cholinergic mechanisms. In: Nordberg A, Fuxe K, Holmstedt B, et al., editors. Nicotinic receptors in the CNS: their role in synaptic transmission. Oxford: Elsevier, 1989: 3–11CrossRefGoogle Scholar
  30. 30.
    Lunell E, Molander L, Ekberg K, et al. Site of nicotine absorption from a vapour inhaler: comparison with cigarette smoking. Eur J Clin Pharmacol 2000; 55(10): 737–41PubMedCrossRefGoogle Scholar
  31. 31.
    Lunell E, Bergström M, Antoni G, et al. Nicotine deposition and body distribution from a nicotine inhaler and a cigarette studied with positron emission tomography. Clin Pharmacol Ther 1996; 58: 593–4CrossRefGoogle Scholar
  32. 32.
    Schneider NG. Nicotine gum in smoking cessation: rationale, efficacy, and proper use. Compr Ther 1987; 13(3): 32–7PubMedGoogle Scholar
  33. 33.
    Cummings S, Hansen B, Richard RJ, et al. Internists and nicotine gum. JAMA 1988; 260: 1565–9PubMedCrossRefGoogle Scholar
  34. 34.
    Rose JE, Jarvik ME, Rose KD. Transdermal administration of nicotine. Drug Alcohol Depend 1984; 13: 209–13PubMedCrossRefGoogle Scholar
  35. 35.
    Gorsline J. Nicotine pharmacokinetics of four nicotine transdermal systems. Health Values 1993; 17(2): 20–4Google Scholar
  36. 36.
    Palmer KJ, Buckley MM, Faulds D. Transdermal nicotine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs 1992; 44(3): 498–529PubMedCrossRefGoogle Scholar
  37. 37.
    Schneider NG. Nicotine nasal spray. Health Values 1994; 18(3): 10–4Google Scholar
  38. 38.
    Blondal T, Franzon M, Westin A. A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation. Eur Respir J 1997; 10(7): 1585–90PubMedCrossRefGoogle Scholar
  39. 39.
    Hjalmarson A, Franzon M, Westin A, et al. Effect of nicotine nasal spray on smoking cessation: a randomized, placebo-controlled, double-blind study. Arch Intern Med 1994; 154: 2567–72PubMedCrossRefGoogle Scholar
  40. 40.
    Sutherland G, Stapleton JA, Russell MAH, et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992; 340: 324–9PubMedCrossRefGoogle Scholar
  41. 41.
    Schneider NG, Olmstead R, Mody F, et al. Efficacy of a nasal nicotine spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction 1995; 90: 1671–82PubMedCrossRefGoogle Scholar
  42. 42.
    Molander L, Lunell E. Pharmacokinetic investigation of a sublingual nicotine tablet. Eur J Clin Pharmacol 2001 Jan-Feb; 56(11): 813–9PubMedCrossRefGoogle Scholar
  43. 43.
    Rose JE, Westman EC, Behm FM, et al. Blockade of smoking satisfaction using the peripheral nicotinic antagonist trimethaphan. Pharmacol Biochem Behav 1999; 62(1): 165–72PubMedCrossRefGoogle Scholar
  44. 44.
    Turner JE, Ellis MP, Oldham RG, et al., inventors. Kabi Pharmacia Aktiebolag, Sweden, assignee. Nicotine-impermeable container and method of fabricating the same. US Patent No. 5,167,242. 1992Google Scholar
  45. 45.
    Leischow SJ. The nicotine vaporizer. Health Values 1994: 18(3): 4–9Google Scholar
  46. 46.
    Glover ED, Glover PN, Nilsson F, et al. Nicotine inhaler (Nicohaler) versus placebo in smoking cessation: a clinical evaluation [abstract]. Society of Behavioral Medicine Proceedings of the 13th Annual Scientific Sessions; 1992 Mar 25–28; New YorkGoogle Scholar
  47. 47.
    Pharmacia. Nicotine inhaler monograph. Chester: Adis International, 1996Google Scholar
  48. 48.
    Russell MAH, Jarvis MJ, Sutherland G, et al. Nicotine replacement in smoking cessation: absorption of nicotine vapour from smoke-free cigarettes. JAMA 1987; 257(23): 3262–5PubMedCrossRefGoogle Scholar
  49. 49.
    Sepkovic DW, Colosimo SG, Axelrad CM, et al. The delivery and uptake of nicotine from an aerosol rod. Am J Public Health 1986; 76: 1343–4PubMedCrossRefGoogle Scholar
  50. 50.
    Hajek P, Jarvis MJ, Belcher M, et al. Effect of smoke-free cigarettes on 24h cigarette withdrawal: a double-blind placebo-controlled study. Psychopharmacology 1989; 97: 99–102PubMedCrossRefGoogle Scholar
  51. 51.
    Nilsson F. Comparative study of the concentrations of nicotine and cotinine from a nicotine inhaler device and after normal smoking of cigarettes. Helsingborg (Sweden): Pharmacia & Upjohn, 1996 (Data on file). Report no.: 9620012Google Scholar
  52. 52.
    Russell MAH, Feyerabend C, Cole PV. Plasma nicotine levels after cigarette smoking and chewing nicotine gum. BMJ 1976; I: 1043–6CrossRefGoogle Scholar
  53. 53.
    Lunell E, Molander L, Andersson S-B. Temperature dependency of the release and bioavailability of nicotine from a nicotine vapour inhaler; in vitro/in vivo correlation. Eur J Clin Pharmacol 1997; 52: 495–500PubMedCrossRefGoogle Scholar
  54. 54.
    Molander L, Lunell E, Andersson S-B, et al. Dose and absolute bioavailability of nicotine from a nicotine vapour inhaler. Clin Pharmacol Ther 1996; 59: 394–400PubMedCrossRefGoogle Scholar
  55. 55.
    Bergström M, Nordberg A, Lunell E, et al. Regional deposition of inhaled 11C-nicotine vapour in the human airways as visualized by positron emission tomography. Clin Pharmacol Ther 1995; 57: 309–17PubMedCrossRefGoogle Scholar
  56. 56.
    Guthrie SK, Zubieta JK, Ohl L, et al. Arterial/venous plasma nicotine concentrations following nicotine nasal spray. Eur J Pharmacol 1999; 55: 639–43CrossRefGoogle Scholar
  57. 57.
    Johansson CJ, Olsson P, Bende M, et al. Absolute bioavailability of nicotine applied to different nasal regions. Eur J Clin Pharmacol 1991; 41: 585–8PubMedCrossRefGoogle Scholar
  58. 58.
    Russell MAH. Nicotine intake and its regulation. J Psychosom Res 1980; 24: 253–64PubMedCrossRefGoogle Scholar
  59. 59.
    Russell MAH, Jarvis MJ, Devitt G, et al. Nicotine intake by snuff users. BMJ 1981; 283(6366): 814–7PubMedCrossRefGoogle Scholar
  60. 60.
    Fagerstrom KO, Tejding R, Westin A, et al. Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker? Tobacco Control 1997; 6: 311–6PubMedCrossRefGoogle Scholar
  61. 61.
    Foulds J, Stapleton J, Feyerabend C, et al. Effect of transdermal nicotine patches on cigarette smoking: a double blind crossover study. Psychopharmacology 1992; 106: 421–7PubMedCrossRefGoogle Scholar
  62. 62.
    Gori GB, Lynch CJ. Analytical cigarette yields as predictors of smoke bioavailability. Regul Toxicol Pharmacol 1985; 5(3): 314–26PubMedCrossRefGoogle Scholar
  63. 63.
    Hjalmarson A, Nilsson F, Sjöström L, et al. The nicotine inhaler in smoking cessation: a double-blind, randomised clinical evaluation. Arch Intern Med 1997; 157: 1721–8PubMedCrossRefGoogle Scholar
  64. 64.
    Jones RL, Nguyen A, Man SF. Nicotine and cotinine replacement when nicotine nasal spray is used to quit smoking. Psychopharmacology 1998; 137(4): 345–50PubMedCrossRefGoogle Scholar
  65. 65.
    Leischow SJ, Valente SN, Hill AL, et al. Effects of nicotine dose and administration method on withdrawal symptoms and side effects during short-term smoking abstinence. Exp Clin Psychopharmacol 1997; 5(1): 54–64PubMedCrossRefGoogle Scholar
  66. 66.
    McNabb ME. Chewing nicotine gum for 3 months: what happens to plasma nicotine levels? Can Med Assoc J 1984; 131: 589–92PubMedGoogle Scholar
  67. 67.
    McNabb ME, Ebert RV, McCusker K. Plasma nicotine levels produced by chewing nicotine gum. JAMA 1982; 248(7): 865–8PubMedCrossRefGoogle Scholar
  68. 68.
    Physicians’ Desk Reference. 49th ed. Montvale (NJ): Medical Economics Data Production Company, 1995Google Scholar
  69. 69.
    Physicians’ Desk Reference. 54th ed. Montvale (NJ): Medical Economics Company, Inc., 2000Google Scholar
  70. 70.
    West RJ, Jarvis MJ, Russell MAH, et al. Effect of nicotine replacement on the cigrette withdrawal syndrome. Br J Addict 1984; 79: 215–9PubMedGoogle Scholar
  71. 71.
    Raw M, Jarvis MJ, Feyerabend C, et al. Comparison of nicotine chewing-gum and psychological treatments for dependent smokers. BMJ 1980; 281(6238): 481–2PubMedCrossRefGoogle Scholar
  72. 72.
    Schneider NG, Olmstead R, Nilsson F, et al. Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. Addiction 1996; 91(9): 1293–306PubMedCrossRefGoogle Scholar
  73. 73.
    Tønnesen P, Nørregaard J, Mikkelsen K, et al. A double-blind trial of a nicotine inhaler for smoking cessation. JAMA 1993; 269(10): 1–5CrossRefGoogle Scholar
  74. 74.
    Tønnesen P, Mikkelsen K, Nørregaard J, et al. Recycling of hard-core smokers with nicotine nasal spray. Eur Respir J 1996; 9(8): 1619–23PubMedCrossRefGoogle Scholar
  75. 75.
    Leischow SJ, Nilsson F, Franzon M, et al. Efficacy of the nicotine inhaler as an adjunct to smoking cessation. Am J Health Behav 1996; 20(5): 364–71Google Scholar
  76. 76.
    Sachs DPL, Säwe U, Leischow S. Nicotine transdermal patch, smoking cessation and gender. In: Harris LS, editor. Problems of drug dependence. Proceedings of the 53rd Annual Scientific Meeting for the Committee on Drug Dependence; 1991 Jun 18; Palm Beach (FL). Washington, DC: USDHHS, 1992. NIDA research monograph 119: publication #92-1888Google Scholar
  77. 77.
    Hurt RD, Dale LC, Fredrickson PA, et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. JAMA 1994; 271: 595–600PubMedCrossRefGoogle Scholar
  78. 78.
    Kenford SL, Fiore MC, Jorenby DE, et al. Predicting smoking cessation: who will quit with and without the nicotine patch. JAMA 1994; 271(8): 589–94PubMedCrossRefGoogle Scholar
  79. 79.
    Silagy C, Mant D, Fowler G, et al. Meta-analysis of efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994; 343: 139–42PubMedCrossRefGoogle Scholar
  80. 80.
    Tang JL, Law M, Wald N. How effective is nicotine replacement therapy in helping people to stop smoking? BMJ 1994; 308(6290): 21–6PubMedCrossRefGoogle Scholar
  81. 81.
    Fiore MC, Smith SS, Jorenby DE, et al. The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. JAMA 1994; 271: 1940–7PubMedCrossRefGoogle Scholar
  82. 82.
    Silagy C, Mant D, Fowler G, et al. Nicotine replacement therapy for smoking cessation (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration, issue 2. Oxford: Oxford Update Software 2000. Available from URL: [Accessed 2001 May 7]
  83. 83.
    American Psychiatric Association. Diagnostic and statistical manual for mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994Google Scholar
  84. 84.
    Hartman N, Caskey NH, Olmstead RE, et al. Nicotine craving and psychiatric diagnosis: past, present and future. Psychiatr Ann 1998; 28(10): 547–51Google Scholar
  85. 85.
    Killen JD, Fortman SP, Newman B, et al. Prospective study of factors influencing the development of craving associated with smoking cessation. Psychopharmacology 1991; 105: 191–6PubMedCrossRefGoogle Scholar
  86. 86.
    Kornitzer M, Boutsen M, Dramaix M, et al. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med 1995; 24(1): 41–7PubMedCrossRefGoogle Scholar
  87. 87.
    Puska P, Korhonen HJ, Vartiainen E, et al. Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia. Tobacco Control 1995; 4: 231–5CrossRefGoogle Scholar
  88. 88.
    Westman EC, Behm FM, Rose JE. Dissociating the nicotine and airway sensory effects of smoking. Pharmacol Biochem Behav 1996; 53(2): 309–15PubMedCrossRefGoogle Scholar
  89. 89.
    Schneider NG, Jacob P, Nilsson F, et al. Saliva cotinine levels as a function of collection method. Addiction 1997; 92(3): 347–51PubMedCrossRefGoogle Scholar
  90. 90.
    Schneider NG, Olmstead RE, Nilsson F, et al. Nicotine inhaler in smoking cessation-a pilot [abstract]. Addiction 1996; 91: 143CrossRefGoogle Scholar
  91. 91.
    Benowitz NL. Pharmacology of nicotine: tolerance and kinetics. In: Henningfield JE, Stitzer ML, editors. New developments in nicotine-delivery systems. Ossining (NY): Cortlandt Communications, 1991: 11–22Google Scholar
  92. 92.
    Hughes JR. Dependence potential and abuse liability of nicotine replacement therapies. Biomed Pharmacother 1989; 43: 11–7PubMedCrossRefGoogle Scholar
  93. 93.
    de Wit H, Bodker B, Ambre J. Rate of increase of plasma drug level influences subjective response in humans. Psychopharmacology 1992; 107: 352–8PubMedCrossRefGoogle Scholar
  94. 94.
    Hughes JR. Dependence on and abuse of nicotine replacement medications: In: Benowitz NL, editor. Nicotine safety and toxicity. New York: Oxford University Press, 1998: 147–57Google Scholar
  95. 95.
    Stitzer M, de Wit H. Abuse liability of nicotine. In: Benowitz NL, editor. Nicotine safety and toxicity. New York: Oxford University Press, 1998; 119–32Google Scholar
  96. 96.
    Hughes JR. Long-term use of nicotine replacement therapy. In: Henningfield JE, Stitzer ML, editors. New developments in nicotine-delivery systems. Ossining (NY): Cortlandt Communications, 1991: 64–71Google Scholar
  97. 97.
    Hatsukami DK, Huber M, Callies A, et al. Physical dependence on nicotine gum: effect of duration of use. Psychopharmacology 1993; 111: 449–56PubMedCrossRefGoogle Scholar
  98. 98.
    Schneider NG. How to use nicotine gum. New York: Simon & Schuster, 1988Google Scholar
  99. 99.
    Schneider NG. Use of 2 mg and 4 mg nicotine gum in an individual treatment trial. In: Ockene JK, editor. The pharmacologic treatment of tobacco dependence. Institute for the Study of Smoking Behavior and Policy. Proceedings of the World Congress; 1985 Nov 4-5; New York. Cambridge (MA): Institute for the Study of Smoking Behavior and Policy, 1986: 233–48Google Scholar
  100. 100.
    Murray RP, Nides MA, Istvan JA, et al. Levels of cotinine associated with long-term ad-libitum nicotine polacrilex use in a clinical trial. Addict Behav 1998; 23(4): 529–35PubMedCrossRefGoogle Scholar
  101. 101.
    Molander L, Lunell E, Fagerstrom KO. Reduction of tobacco withdrawal symptoms with a sublingual nicotine tablet: a placebo controlled study. Nicotine Tob Res 2000; 2: 187–91PubMedCrossRefGoogle Scholar
  102. 102.
    Schuh KJ, Schuh LM, Henningfield JE, et al. Nicotine nasal spray and vapor inhaler: abuse liability assessment. Psychopharmacology 1997; 130: 352–61PubMedCrossRefGoogle Scholar
  103. 103.
    Fant RV, Owen LL, Henningfield JE. Nicotine replacement therapy. Prim Care 1999; 26(3): 633–52PubMedCrossRefGoogle Scholar
  104. 104.
    Tonnesen P, Fryd V, Hansen M, et al. Two and four mg nicotine chewing gum and group counseling in smoking cessation: an open, randomized, controlled trial with a 22 month follow-up. Addict Behav 1988; 13(1): 17–27PubMedCrossRefGoogle Scholar
  105. 105.
    Herrera N, Franco R, Herrera L, et al. Nicotine gum, 2 and 4 mg, for nicotine dependence; a double-blind placebo-controlled trial within a behavior modification support program. Chest 1995; 108(2): 447–51PubMedCrossRefGoogle Scholar
  106. 106.
    Fagerstrom KO, Schneider NG, Lunell E. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology 1993; 111: 271–7PubMedCrossRefGoogle Scholar
  107. 107.
    Blondal T, Gudmundsson LJ, Olafsdottir I, et al. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up [published erratum appears in BMJ 1999; 318 (7186): 764]. BMJ 1999; 318(7179): 285–8PubMedCrossRefGoogle Scholar
  108. 108.
    Westman EC, Tomlin KF, Rose JE, et al. The combination of nicotine inhaler and nicotine patch for smoking cessation: a pilot study. Am J Health Behav 2000; 24(2): 114–9CrossRefGoogle Scholar
  109. 109.
    Bohadana A, Nilsson F, Rasmussen T, et al. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind controlled trial. Arch Intern Med 2000 Nov 13; 160(20): 3128–34PubMedCrossRefGoogle Scholar
  110. 110.
    Blondal T, Gudmundsson LJ, Tomasson K, et al. The effects of fluoxetine combined with nicotine inhalers in smoking cessation: a randomized trial. Addiction 1999; 94(7): 1007–15PubMedCrossRefGoogle Scholar
  111. 111.
    Etter JF, Perneger TV, Ronchi A. Distributions of smokers by stage: international comparison and association with smoking prevalence. Prev Med 1997; 26: 580–5PubMedCrossRefGoogle Scholar
  112. 112.
    Hughes JR, Cummings KM, Hyland A. Ability of smokers to reduce their smoking and its association with future smoking cessation. Addiction 1999 Jan; 94(1): 109–14PubMedCrossRefGoogle Scholar
  113. 113.
    Hughes JR. Reduced smoking: an introduction and review of the evidence. Addiction 2000; 95 (1 Suppl.): 3S–7SGoogle Scholar
  114. 114.
    Benowitz NL. Clinical pharmacology of nicotine. Annu Rev Med 1986; 37: 21–32PubMedCrossRefGoogle Scholar
  115. 115.
    Jimenez-Ruiz C, Kunze M, Fagerström KO. Nicotine replacement: a new approach to reducing tobacco-related harm. Eur Respir J 1998; 11(2): 473–9PubMedCrossRefGoogle Scholar
  116. 116.
    Rennard SI, Daughton D, Fujita J, et al. Short-term smoking reduction is associated with reduction in measures of lower respiratory tract inflammation in heavy smokers. Eur Respir J; 1990; 3: 752–9PubMedGoogle Scholar
  117. 117.
    Bolliger CT, Zellweger J-P, Danielsson T, et al. Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety. BMJ 2000 Aug 5; 321(7257): 329–33PubMedCrossRefGoogle Scholar
  118. 118.
    Schneider NG. Nicotine therapy in smoking cessation: pharmacokinetic considerations. Clin Pharmacokinet 1992; 23(3): 169–72PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Nina G. Schneider
    • 1
    • 2
  • Richard E. Olmstead
    • 1
    • 2
  • Mikael A. Franzon
    • 3
  • Erik Lunell
    • 4
  1. 1.University of California-Los Angeles, School of MedicineLos AngelesUSA
  2. 2.Nicotine Research UnitVA-Greater Los Angeles Healthcare SystemWest Los AngelesUSA
  3. 3.Pharmacia Consumer HealthcareBridgewaterUSA
  4. 4.Department of Clinical PharmacologyUniversity HospitalLundSweden

Personalised recommendations